JOP20210279A1 - طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي - Google Patents

طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي

Info

Publication number
JOP20210279A1
JOP20210279A1 JOP/2021/0279A JOP20210279A JOP20210279A1 JO P20210279 A1 JOP20210279 A1 JO P20210279A1 JO P20210279 A JOP20210279 A JO P20210279A JO P20210279 A1 JOP20210279 A1 JO P20210279A1
Authority
JO
Jordan
Prior art keywords
psoriatic arthritis
methods
treating cases
treating
cases
Prior art date
Application number
JOP/2021/0279A
Other languages
Arabic (ar)
English (en)
Inventor
Kirti Wardhaman Ganorkar
Anil Raghavan
Atul Mathuradas Raut
Siu-Long Yao
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72837755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20210279(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of JOP20210279A1 publication Critical patent/JOP20210279A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JOP/2021/0279A 2019-04-15 2021-10-14 طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي JOP20210279A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921015050 2019-04-15
IN202021004422 2020-01-31
PCT/IB2020/053565 WO2020212874A1 (en) 2019-04-15 2020-04-15 Methods for treatment of subjects with psoriatic arthritis

Publications (1)

Publication Number Publication Date
JOP20210279A1 true JOP20210279A1 (ar) 2021-10-14

Family

ID=72837755

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0279A JOP20210279A1 (ar) 2019-04-15 2021-10-14 طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي

Country Status (16)

Country Link
US (1) US20220298233A1 (https=)
EP (1) EP3956357A4 (https=)
JP (2) JP7628962B2 (https=)
KR (1) KR20210140780A (https=)
CN (1) CN113825768A (https=)
AU (1) AU2020259375A1 (https=)
BR (1) BR112021020612A2 (https=)
CA (1) CA3143604A1 (https=)
IL (1) IL287213A (https=)
JO (1) JOP20210279A1 (https=)
MA (1) MA55729A (https=)
MX (1) MX2021012652A (https=)
MY (1) MY210310A (https=)
PH (1) PH12021552536A1 (https=)
SG (1) SG11202111056YA (https=)
WO (1) WO2020212874A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121843958A (zh) * 2023-08-11 2026-04-10 信达生物医药科技(杭州)有限公司 既往接受生物制剂治疗斑块状银屑病的受试者转用抗IL23p19抗体治疗斑块状银屑病的方法
AU2024338774A1 (en) * 2023-09-07 2026-03-26 Innovent Biologics (Suzhou) Co., Ltd. Method for treating moderate and severe psoriasis using recombinant anti-il-23p19 antibody
WO2026069253A1 (en) * 2024-09-30 2026-04-02 Sun Pharmaceutical Industries Limited Long term safety of tildrakizumab in psoriatic arthritis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
WO2008063213A2 (en) * 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
ES2708988T3 (es) * 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
EP2331078B1 (en) * 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Lyophilized formulations of engineered anti-il-23p19 antibodies
MX2019000046A (es) * 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
ES2729603T3 (es) * 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19

Also Published As

Publication number Publication date
SG11202111056YA (en) 2021-11-29
EP3956357A1 (en) 2022-02-23
BR112021020612A2 (pt) 2021-12-28
WO2020212874A1 (en) 2020-10-22
IL287213A (en) 2021-12-01
US20220298233A1 (en) 2022-09-22
EP3956357A4 (en) 2023-01-04
JP7628962B2 (ja) 2025-02-12
MA55729A (fr) 2022-02-23
MX2021012652A (es) 2022-01-24
MY210310A (en) 2025-09-10
JP2025069284A (ja) 2025-04-30
CA3143604A1 (en) 2020-10-22
KR20210140780A (ko) 2021-11-23
PH12021552536A1 (en) 2022-07-04
CN113825768A (zh) 2021-12-21
AU2020259375A1 (en) 2021-10-28
JP2022529266A (ja) 2022-06-20

Similar Documents

Publication Publication Date Title
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
JOP20200078A1 (ar) أجسام مضادة خاصة بـ cd47 وpd-l1
CR20200467A (es) Agentes anticuerpos anti-cd25
JOP20190292A1 (ar) استخدام الأجسام المضادة لربط il-1? في علاج السرطان
NZ782442A (en) Antibodies that bind cd39 and uses thereof
MX2021000745A (es) Composiciones anti-cd112r y metodos.
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
MX2025000260A (es) Proteina de union al antigeno anti-steap1
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
JOP20220161A1 (ar) جسم مضاد لـ lilrb1 واستخداماته
JOP20210297A1 (ar) مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية
PH12021550332A1 (en) Anti-cd33 antibodies and methods of use thereof
JOP20210279A1 (ar) طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي
MX2020009037A (es) Anticuerpos de b7-h4 y métodos para usarlos.
CY1125536T1 (el) Συνθεσεις για τη θεραπεια της αμυλοειδωσης
MX2021004114A (es) Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
AR115257A1 (es) Anticuerpos de fijación a bcma y sus usos
EA201891594A1 (ru) Антитела к il-17c
MX2023006777A (es) Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
IL288477A (en) Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
PH12020551451A1 (en) Anti-cd25 for tumour specific cell depletion
PH12018501674A1 (en) Anti-citrullinated hla polypeptide antibodies and uses thereof